RT Journal Article
T1 Results from the European Prospective Investigation into Cancer and Nutrition Link Vitamin B6 Catabolism and Lung Cancer Risk.
A1 Zuo, Hui
A1 Ueland, Per M
A1 Midttun, Øivind
A1 Vollset, Stein E
A1 Tell, Grethe S
A1 Theofylaktopoulou, Despoina
A1 Travis, Ruth C
A1 Boutron-Ruault, Marie-Christine
A1 Fournier, Agnès
A1 Severi, Gianluca
A1 Kvaskoff, Marina
A1 Boeing, Heiner
A1 Bergmann, Manuela M
A1 Fortner, Renée T
A1 Kaaks, Rudolf
A1 Trichopoulou, Antonia
A1 Kotanidou, Anastasia
A1 Lagiou, Pagona
A1 Palli, Domenico
A1 Sieri, Sabina
A1 Panico, Salvatore
A1 Bueno-de-Mesquita, H Bas
A1 Peeters, Petra H
A1 Grankvist, Kjell
A1 Johansson, Mikael
A1 Agudo, Antonio
A1 Garcia, Jose Ramon Quiros
A1 Larranaga, Nerea
A1 Sanchez-Perez, Maria-Jose
A1 Chirlaque, Maria Dolores
A1 Ardanaz, Eva
A1 Chuang, Shu-Chun
A1 Gallo, Valentina
A1 Brennan, Paul
A1 Johansson, Mattias
A1 Ulvik, Arve
AB Circulating pyridoxal-5'-phosphate (PLP) has been linked to lung cancer risk. The PAr index, defined as the ratio 4-pyridoxic acid/(pyridoxal + PLP), reflects increased vitamin B6 catabolism during inflammation. PAr has been defined as a marker of lung cancer risk in a prospective cohort study, but analysis of a larger numbers of cases are needed to deepen the significance of this study. Here, we conducted a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC, n = 521,330), which included 892 incident lung cancer cases and 1,748 controls matched by center, gender, date of blood collection, and date of birth. The association of PAr with risk of lung cancer was evaluated by using conditional logistic regression. Study participants with elevated PAr experienced higher risk of lung cancer in a dose-response fashion, with a doubling in PAr levels associated with 52% higher odds of lung cancer after adjustment for tobacco smoking, serum cotinine levels, educational attainment, and BMI [OR, 1.52; 95% confidence interval (CI) 1.27-1.81; P
YR 2017
FD 2017-10-25
LK http://hdl.handle.net/10668/11731
UL http://hdl.handle.net/10668/11731
LA en
DS RISalud
RD Apr 20, 2025